Literature DB >> 7679432

Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies.

S R Zhou1, J N Whitaker.   

Abstract

Acetylated peptide 1-9 from human myelin basic protein induces experimental allergic encephalomyelitis in PL/J mice through I-Au and TCR V beta 8.2. Murine mAb anti-Id directed against murine mAb to myelin basic protein peptide acetyl 1-9 was examined for effects on in vitro and in vivo T cell activities. Certain anti-Id, generated in PL/J mice, inhibited Ag-specific proliferation and IL-2 production and precipitated surface receptors having features of the TCR. The idiotypic features of TCR recognition were demonstrated by showing that binding of anti-Id to the TCR could be blocked by anti-TCR alpha beta and anti-TCR V beta 8.1-8.2 but not by murine Ig or anti-TCR V beta 17a. In addition, the anti-Id did not react with TCR V beta 8.2 transgenically inserted into MRL+/+ mice. One anti-Id was also capable of lessening clinical disease activity in the adoptive passive transfer model of experimental allergic encephalomyelitis in PL/J mice. These results indicate that anti-Id may recognize a cross-reactive Id on T cells, presumably on the TCR, responsive to the same I-Au-restricted encephalitogenic myelin basic protein peptide in PL/J mice. The selective development of anti-Id and their effect on T cell-mediated tissue damage provide a method for applying specific anti-Id antibodies to modify experimental and, possibly, spontaneous diseases of autoimmune demyelination.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679432

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation.

Authors:  Y Shoenfeld; I Krause; M Blank
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

3.  Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression.

Authors:  I Krause; M Blank; Y Levi; T Koike; V Barak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

4.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Authors:  Anne H Cross; Jennifer L Stark; Joanne Lauber; Michael J Ramsbottom; Jeri-Anne Lyons
Journal:  J Neuroimmunol       Date:  2006-08-14       Impact factor: 3.478

Review 5.  The potential role of B cell-targeted therapies in multiple sclerosis.

Authors:  Aaron Boster; Daniel P Ankeny; Michael K Racke
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

6.  Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

Authors:  M Blank; J Manosroi; Y Tomer; A Manosroi; J Kopolovic; S Charcon-Polak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

7.  Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.

Authors:  S Araga; R D LeBoeuf; J E Blalock
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

8.  Murine V lambda x and V lambda x-containing antibodies bind human myelin basic protein.

Authors:  F S Galin; C C Maier; S R Zhou; J N Whitaker; J E Blalock
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

9.  Genetic control of anti-idiotypic vaccination against coronavirus infection.

Authors:  M W Yu; S Lemieux; P J Talbot
Journal:  Eur J Immunol       Date:  1996-12       Impact factor: 5.532

10.  Antigenized antibodies expressing Vbeta8.2 TCR peptides immunize against rat experimental allergic encephalomyelitis.

Authors:  Cristina Musselli; Svetlana Daverio-Zanetti; Maurizio Zanetti
Journal:  J Immune Based Ther Vaccines       Date:  2004-11-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.